AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17877674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 micrograms)
Number of subjects: 170
Study 17877674 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (50 micrograms)
Number of subjects: 170
Study 14742367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Trick (CT) procedure
Number of subjects: 20
Study 14742367 — intervention group
Group type: COMPARATOR
Intervention: No Cough Trick (Control)
Number of subjects: 20
Study 10967152 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 24
Study 10967152 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (12 microg twice daily)
Number of subjects: 24
Study 10967152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8629926 — intervention group
Group type: EXPERIMENTAL
Intervention: Spastic group
Number of subjects: 32
Study 8629926 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 32
Study 1351196 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized hospital practice (PHP)
Number of subjects: 100
Study 1351196 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital practice (Control)
Number of subjects: 100
Study 6367635 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (23 mg, dissolved every 2 hours after an initial double dose)
Number of subjects: 65
Study 6367635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30131280 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic eyewear
Number of subjects: 22
Study 30131280 — intervention group
Group type: COMPARATOR
Intervention: Normal vision (Control)
Number of subjects: 22
Study 30247384 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline spikes
Number of subjects: 123
Study 26981934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 932
Study 26981934 — intervention group
Group type: COMPARATOR
Intervention: Control (expectant management)
Number of subjects: 932
Study 24286966 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12) intervention
Number of subjects: 234
Study 22590530 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant cries (low and high distress)
Number of subjects: 17
Study 22590530 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy infant faces
Number of subjects: 17
Study 22590530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad infant faces
Number of subjects: 17
Study 22590530 — intervention group
Group type: EXPERIMENTAL
Intervention: High-distress cries
Number of subjects: 17
Study 22590530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-distress cries
Number of subjects: 17
Study 22590530 — intervention group
Group type: COMPARATOR
Intervention: Pink noise
Number of subjects: 17
Study 20924011 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% saline/6% dextran (hypertonic saline/dextran)
Number of subjects: 1282
Study 20924011 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% saline (hypertonic saline)
Number of subjects: 1282
Study 20924011 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (normal saline)
Number of subjects: 1282
Study 20924011 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (hypertonic saline/dextran, hypertonic saline, normal saline)
Number of subjects: 1282
Study 18957124 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 35
Study 18957124 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 200 mg
Number of subjects: 35
Study 15781758 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin high dose (1.0 mg/kg per day) for 1 year followed by moderate dose (0.5 mg/kg per day) for 2 years
Number of subjects: 151
Study 15781758 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin moderate dose (0.5 mg/kg per day) for 3 years
Number of subjects: 151
Study 15781758 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 years
Number of subjects: 151
Study 14520221 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced contraceptive counseling, initial provision of contraception, and facilitated referral to a PCP
Number of subjects: 877
Study 14520221 — intervention group
Group type: COMPARATOR
Intervention: Control group (condoms with spermicide and referral list only)
Number of subjects: 877
Study 10648315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 5 mg
Number of subjects: 50
Study 10648315 — intervention group
Group type: COMPARATOR
Intervention: Saline IV (Control)
Number of subjects: 50
Study 8879891 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of cefdinir once daily (QD) for 10 days
Number of subjects: 466
Study 8879891 — intervention group
Group type: COMPARATOR
Intervention: 300 mg of cefdinir twice daily (BID) for 10 days
Number of subjects: 466
Study 1379664 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 80 mg/M2 on day 1 and 5-fluorouracil 800 mg/M2 days 2 through 6 (two-drug regimen)
Number of subjects: 62
Study 1379664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/M2 on day 1, 5-fluorouracil 800 mg/M2 days 2 through 6, plus 15 U bleomycin on day 1 and methotrexate 100 mg/M2 on day 16 followed by 15 mg leucovorin every 6 hours for six doses (four-drug regimen)
Number of subjects: 62
Study 1379664 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 62
Study 1379664 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 62
Study 31831364 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of serum hepatocyte growth factor (HGF) in patients with dyslipidemia
Number of subjects: 3027
Study 31831364 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of serum hepatocyte growth factor (HGF) in patients with normal lipids
Number of subjects: 3027
Study 31831364 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding HGF to conventional risk factors in patients with dyslipidemia
Number of subjects: 3027
Study 31831364 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C levels in ischemic stroke patients
Number of subjects: 3027
Study 30600702 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 vaccine only
Number of subjects: 12
Study 30600702 — intervention group
Group type: COMPARATOR
Intervention: IL-2, GM-CSF, and rhGH immunotherapy with or without vaccine
Number of subjects: 12
Study 28587609 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 625
Study 28587609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Number of subjects: 625
Study 28587609 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 625
Study 28587609 — intervention group
Group type: EXPERIMENTAL
Intervention: BBTI
Number of subjects: 625
Study 28587609 — intervention group
Group type: EXPERIMENTAL
Intervention: SHUTi
Number of subjects: 625
Study 28587609 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 625
Study 25891091 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple anti-platelet therapy (TAT; aspirin, clopidogrel, and sarpogrelate)
Number of subjects: 220
Study 25891091 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Number of subjects: 220
Study 23663651 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy (CBT) - 15 sessions directed at symptom reduction of SUD and ADHD
Number of subjects: 0
Study 23663651 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual - 10 CBT sessions directed at symptom reduction of SUD only
Number of subjects: 0
Study 21875859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 1944
Study 21875859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1944
Study 20303665 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (12-week treatment)
Number of subjects: 401
Study 17593025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemtuzumab ozogamicin (GO) added to FLAI chemotherapy
Number of subjects: 46
Study 17593025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemtuzumab ozogamicin (GO)
Number of subjects: 46
Study 17593025 — intervention group
Group type: COMPARATOR
Intervention: FLAI chemotherapy without GO (historical cohort)
Number of subjects: 46
Study 15888715 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 37
Study 15888715 — intervention group
Group type: COMPARATOR
Intervention: Cast treatment
Number of subjects: 37
Study 12468610 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplements
Number of subjects: 196
Study 12468610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 9812128 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Number of subjects: 16
Study 9812128 — intervention group
Group type: COMPARATOR
Intervention: Left prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Number of subjects: 16
Study 7639163 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg verapamil
Number of subjects: 287
Study 7639163 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg verapamil
Number of subjects: 287
Study 7639163 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg verapamil
Number of subjects: 287
Study 7639163 — intervention group
Group type: EXPERIMENTAL
Intervention: 540 mg verapamil
Number of subjects: 287
Study 7639163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 2495215 — intervention group
Group type: EXPERIMENTAL
Intervention: Deponit 5
Number of subjects: 47
Study 2495215 — intervention group
Group type: COMPARATOR
Intervention: Transiderm-Nitro 5
Number of subjects: 47
Study 326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyclidine
Number of subjects: 16
Study 326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 16
Study 326325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29926254 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbitrary face-bow transfer
Number of subjects: 38
Study 29926254 — intervention group
Group type: COMPARATOR
Intervention: Average values transfer
Number of subjects: 38
Study 28735965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1790GAHB vaccine at doses ≥1.5/25μg
Number of subjects: 102
Study 28735965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1790GAHB vaccine at doses up to 5.9/100μg
Number of subjects: 102
Study 28735965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal and intranasal administration of 1790GAHB vaccine
Number of subjects: 102
Study 28735965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26100336 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 26100336 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study 23898925 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 102
Study 23898925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 21729566 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF during the steady rise of the WBC count (5 µg/kg subcutaneously until final PBSC apheresis)
Number of subjects: 39
Study 21729566 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF subcutaneously (filgrastim) at the first restoration after the initial nadir of the peripheral WBC count (historical control group)
Number of subjects: 39
Study 19383225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyposis tissue samples
Number of subjects: 0
Study 19383225 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal tissue samples)
Number of subjects: 0
Study 16723054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine (300 or 400 mg)
Number of subjects: 162
Study 16723054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine (high-concentration/low-volume)
Number of subjects: 162
Study 16723054 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 162
Study 15314047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical patient lifts
Number of subjects: 61
Study 11051596 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc
Number of subjects: 34
Study 11051596 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 34
Study 11051596 — intervention group
Group type: COMPARATOR
Intervention: Control (IFN-alpha only)
Number of subjects: 34
Study 9376990 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 (chimeric monoclonal antibody)
Number of subjects: 0
Study 9376990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7680852 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (nasopharyngeal temperature > 34 degrees C)
Number of subjects: 60
Study 7680852 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic bypass and administration of high‐dose aprotinin (2 million IU before CPB, 500,000 IU/h until the end of the operation, and 2 million IU added to the prime)
Number of subjects: 60
Study 7680852 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB (nasopharyngeal temperature < 28 degrees C)
Number of subjects: 60
Study 7680852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB and aprotinin
Number of subjects: 60
Study 3531052 — intervention group
Group type: EXPERIMENTAL
Intervention: Trestatin 10 mg
Number of subjects: 0
Study 3531052 — intervention group
Group type: EXPERIMENTAL
Intervention: Trestatin 3 mg
Number of subjects: 0
Study 3531052 — intervention group
Group type: COMPARATOR
Intervention: Trestatin 50 mg
Number of subjects: 0
Study 3531052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29098379 — intervention group
Group type: EXPERIMENTAL
Intervention: High height difference position
Number of subjects: 30
Study 29098379 — intervention group
Group type: COMPARATOR
Intervention: Control group (corrected hydrostatic pressure)
Number of subjects: 30
Study 29098379 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for hydrostatic pressure
Number of subjects: 30
Study 25886707 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids supplementation
Number of subjects: 26
Study 25886707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24168957 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical management (antiplatelet therapy, intensive management of vascular risk factors, lifestyle-modification programme)
Number of subjects: 451
Study 24168957 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive medical management plus stenting with the Wingspan stent
Number of subjects: 451
Study 24168957 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical management
Number of subjects: 451
Study 22982768 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal pre-school vision screening (PVS) conducted by nurses/CMAs and physicians
Number of subjects: 45
Study 22982768 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing visual acuity by nurses/CMAs
Number of subjects: 45
Study 22982768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision screening by physicians
Number of subjects: 45
Study 22982768 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to PVS
Number of subjects: 45
Study 20521033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 3,900 mg
Number of subjects: 49
Study 20521033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 49
Study 20521033 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 49
Study 18695807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile gauze dressings
Number of subjects: 150
Study 18695807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterilized transparent film dressings
Number of subjects: 150
Study 18695807 — intervention group
Group type: EXPERIMENTAL
Intervention: Non sterile hypoallergenic adhesive tape
Number of subjects: 150
Study 15643191 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2% glyceryl trinitrate (GTN) paste
Number of subjects: 134
Study 15643191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 11801420 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of a motoric act (Obs-grasp)
Number of subjects: 15
Study 11801420 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of a complex motoric act (Obs-seq)
Number of subjects: 15
Study 11801420 — intervention group
Group type: COMPARATOR
Intervention: Relax (absence of tasks)
Number of subjects: 15
Study 11801420 — intervention group
Group type: COMPARATOR
Intervention: Actual motor performance
Number of subjects: 15
Study 10790903 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention to reduce excessive drinking, smoking, and stress
Number of subjects: 954
Study 10790903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 954
Study 10790903 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 954
Study 7779733 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (55 Gy in 32-36 fractions of 1.72-1.53 Gy, twice daily for 3 weeks)
Number of subjects: 116
Study 7779733 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy
Number of subjects: 116
Study 2264602 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers for treatment study
Number of subjects: 0
Study 2264602 — intervention group
Group type: COMPARATOR
Intervention: Non-volunteers for treatment study
Number of subjects: 0
Study 6986969 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 89
Study 6986969 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF chemotherapy
Number of subjects: 89
Study 31654573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ARC-520
Number of subjects: 90
Study 31654573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg ARC-520
Number of subjects: 90
Study 31654573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 90
Study 31654573 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-520
Number of subjects: 90
Study 29020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS)
Number of subjects: 20
Study 29020806 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 27564385 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic medications (AC)
Number of subjects: 231
Study 27564385 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox
Number of subjects: 231
Study 25380901 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose tacrolimus (group I)
Number of subjects: 29
Study 25380901 — intervention group
Group type: COMPARATOR
Intervention: Reduced dose tacrolimus (group II)
Number of subjects: 29
Study 22517886 — intervention group
Group type: COMPARATOR
Intervention: Control information about cervical cancer
Number of subjects: 606
Study 22517886 — intervention group
Group type: EXPERIMENTAL
Intervention: Details of the link between HPV and cervical cancer
Number of subjects: 606
Study 22517886 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor information
Number of subjects: 606
Study 22517886 — intervention group
Group type: EXPERIMENTAL
Intervention: Details about the link with HPV + risk factor information
Number of subjects: 606
Study 19594741 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant hormone therapy (NHT) with goserelin acetate and flutamide before radical prostatectomy (RP)
Number of subjects: 148
Study 19594741 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP) only
Number of subjects: 148
Study 17631708 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus imported LMWH treatment group
Number of subjects: 75
Study 17631708 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus indigenous LMWH treatment group
Number of subjects: 75
Study 17631708 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 75
Study 15681099 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (CHOD) 12.6g/100ml, 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Number of subjects: 65
Study 15681099 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (control group), 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Number of subjects: 65
Study 15681099 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (CHOD)
Number of subjects: 65
Study 15681099 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (control group)
Number of subjects: 65
Study 15681099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 11947915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily for 16 weeks
Number of subjects: 136
Study 11947915 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 1200 mg daily for 16 weeks
Number of subjects: 136
Study 11947915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pravastatin and gemfibrozil
Number of subjects: 136
Study 10487682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose test (LDT)
Number of subjects: 42
Study 10487682 — intervention group
Group type: COMPARATOR
Intervention: Standard dose test (SDT)
Number of subjects: 42
Study 8768619 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 24
Study 1872266 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466
Study 1872266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2466
Study 6345373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 12